Torrent Pharma Q1 net profit rises 20% on broad-based growth

AHMEDABAD: Homegrown pharma major, Torrent Pharmaceuticals, reported a 20% year-on-year increase in net profit to Rs 548 crore for the first quarter of FY26. This growth was driven by strong performance across its India, US, and Brazil markets.The company’s consolidated revenue grew 11% to Rs 3,178 crore, while operating EBITDA rose 14% to Rs 1,032 crore. Adjusted for one-time acquisition-related costs of Rs 15 crore, EBITDA stood at Rs 1,047 crore, with a margin of 32.9%. The gross margin remained stable at 76%, and R&D spend grew 16% to Rs 157 crore.The India business, which contributed over half of its total sales, recorded revenues of Rs 1,811 crore, up 11% year-on-year, led by strong growth in chronic therapies.

Torrent’s chronic portfolio expanded 13%, outpacing the Indian Pharmaceutical Market’s 9% growth, as per AIOCD data.

In the US, Torrent Pharma revenues rose 19% to Rs 308 crore, with new launches achieving targeted market share. Brazil revenues grew 11% to Rs 218 crore, or 16% in constant currency terms, bolstered by key brand performance and new product introductions. Germany saw 9% growth to Rs 308 crore, though constant currency sales rose just 1% due to supply disruptions at a third-party facility. Despite this, Torrent maintained steady margins and expects continued growth across geographies.